Blood:微调FOXO3A,是cHL的一种生存机制,也是流产性浆细胞分化的标志

2018-02-14 MedSci MedSci原创

中心点:FOXO3A表达提示cHL的流产性PC分化状态。严格调控FOXO3A的表达,与cHL的病程发展至关重要。摘要:近期有研究人员发现抑制FOXO1可促进经典霍奇金淋巴瘤(cHL)的病程发展。有趣的是,另报道发现FOXO3A,FOXO家族的另一个成员,在cHL的恶性HRS细胞中的表达水平明显高于在非霍奇金淋巴瘤(NHL)亚型的表达水平。因此,研究人员对FOXO3A在cHL的潜在作用及维持其水平的

中心点:

FOXO3A表达提示cHL的流产性PC分化状态。

严格调控FOXO3A的表达,与cHL的病程发展至关重要。

摘要:

近期有研究人员发现抑制FOXO1可促进经典霍奇金淋巴瘤(cHL)的病程发展。有趣的是,另报道发现FOXO3A,FOXO家族的另一个成员,在cHL的恶性HRS细胞中的表达水平明显高于在非霍奇金淋巴瘤(NHL)亚型的表达水平。因此,研究人员对FOXO3A在cHL的潜在作用及维持其水平的调控机制进行深入研究。

经实验发现,cHL中的高FOXO3A水平对应B细胞特异性分化模式。在生发中心母细胞(CB)分化成浆细胞(PC)的过程中,B细胞中FOXO3A的表达量增加。cHL的FOXO3A水平高于生发中心(GC)的B细胞,但低于终末分化的浆细胞。cHL中FOXO3A的中等表达水平或许提示cHL的“流产性PC分化”亚型。此外,研究人员还发现,由PC转录因子PRDM1α激活所诱导的cHL细胞系也过表达FOXO3A,进一步证明了上述假设。研究人员还发现,MIR155和ERK本构激活可抑制cHL的FOXO3A表达。最后,研究人员通过RNA干扰技术证实了FOXO3A在cHL中的重要性。

总而言之,FOXO3A表达水平的严格调控可促进cHL的病程进展、形成特异性亚型。

原始出处

Clarissa D.Osswald,et al. Fine tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation. Blood  2018  :blood-2017-07-795278;  doi: https://doi.org/10.1182/blood-2017-07-795278

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1985299, encodeId=32b2198529967, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4663, encryptionId=186046636e, topicName=cHL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Wed Feb 14 21:12:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024540, encodeId=4626202454020, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 03 07:12:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466606, encodeId=789214666060c, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570197, encodeId=984215e01977b, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288126, encodeId=e396288126a8, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Feb 15 09:08:05 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287907, encodeId=caf828e90769, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Wed Feb 14 13:20:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1985299, encodeId=32b2198529967, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4663, encryptionId=186046636e, topicName=cHL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Wed Feb 14 21:12:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024540, encodeId=4626202454020, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 03 07:12:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466606, encodeId=789214666060c, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570197, encodeId=984215e01977b, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288126, encodeId=e396288126a8, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Feb 15 09:08:05 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287907, encodeId=caf828e90769, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Wed Feb 14 13:20:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-05-03 hyf028
  3. [GetPortalCommentsPageByObjectIdResponse(id=1985299, encodeId=32b2198529967, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4663, encryptionId=186046636e, topicName=cHL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Wed Feb 14 21:12:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024540, encodeId=4626202454020, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 03 07:12:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466606, encodeId=789214666060c, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570197, encodeId=984215e01977b, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288126, encodeId=e396288126a8, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Feb 15 09:08:05 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287907, encodeId=caf828e90769, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Wed Feb 14 13:20:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1985299, encodeId=32b2198529967, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4663, encryptionId=186046636e, topicName=cHL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Wed Feb 14 21:12:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024540, encodeId=4626202454020, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 03 07:12:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466606, encodeId=789214666060c, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570197, encodeId=984215e01977b, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288126, encodeId=e396288126a8, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Feb 15 09:08:05 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287907, encodeId=caf828e90769, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Wed Feb 14 13:20:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1985299, encodeId=32b2198529967, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4663, encryptionId=186046636e, topicName=cHL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Wed Feb 14 21:12:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024540, encodeId=4626202454020, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 03 07:12:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466606, encodeId=789214666060c, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570197, encodeId=984215e01977b, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288126, encodeId=e396288126a8, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Feb 15 09:08:05 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287907, encodeId=caf828e90769, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Wed Feb 14 13:20:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-15 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1985299, encodeId=32b2198529967, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4663, encryptionId=186046636e, topicName=cHL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Wed Feb 14 21:12:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024540, encodeId=4626202454020, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 03 07:12:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466606, encodeId=789214666060c, content=<a href='/topic/show?id=8d3e65434d4' target=_blank style='color:#2F92EE;'>#浆细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65434, encryptionId=8d3e65434d4, topicName=浆细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=181c6846356, createdName=huangshifeng, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570197, encodeId=984215e01977b, content=<a href='/topic/show?id=a66ae7809b1' target=_blank style='color:#2F92EE;'>#细胞分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77809, encryptionId=a66ae7809b1, topicName=细胞分化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=653c15636865, createdName=karmond, createdTime=Fri Feb 16 03:12:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288126, encodeId=e396288126a8, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Feb 15 09:08:05 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287907, encodeId=caf828e90769, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Wed Feb 14 13:20:14 CST 2018, time=2018-02-14, status=1, ipAttribution=)]
    2018-02-14 紫迎馨

    关注

    0

相关资讯

NCCN临床实践指南:霍奇金淋巴瘤(2018.V1)

2017年12月,美国国家综合癌症网络(NCCN)发布了霍奇金淋巴瘤指南,2018年第1版,指南更新摘要如下: 诊断和检查 经典霍奇金淋巴瘤的临床分期 完成治疗后随访和副作用监测 耐药或疑似复发经典型霍奇金淋巴瘤 I–II期典型霍奇金淋巴瘤不利的风险因素 系统治疗原则 放射治疗原则 PET-5绩点量表 复发或难治性疾病的系统治疗原则 老年典型霍奇金淋巴瘤的管理 分期

Blood:Brentuximab vedotin联合nivolumab用于治疗霍奇金淋巴瘤的效果。

BV联合Nivo,是一种耐受性良好的抢救方案,用于难治性/复发性典型霍奇金淋巴瘤患者,不足10%的患者发生需要系统性应用类固醇激素治疗的IrAEs。 BV联合Nivo治疗难治性/复发性典型霍奇金淋巴瘤患者,完全反应率61%,总体反应率82%,患者可继续进行干细胞移植,且无明显副作用。

Lancet:PET指导晚期霍奇金淋巴瘤的治疗

研究认为,PET阳性的晚期霍奇金淋巴瘤患者,在强化治疗基础上联合利妥昔单抗不会改善患者预后,而对于PET阴性患者,减少强化治疗至4轮也不会影响对疾病的控制。PET-2指导的eBEACOPP强化治疗方案可有效控制疾病并且减少治疗毒副作用,有望成为今后晚期霍奇金淋巴瘤治疗的首选方法

CLIN CANCER RES:非霍奇金淋巴瘤和霍奇金淋巴瘤过表达BCLW

B细胞淋巴瘤在进展过程中必然会出现凋亡抵抗。最近的研究发现BCLW,一个抗凋亡BCL2家族成员,过去认为仅对精子生成过程有影响,在弥漫大B淋巴瘤和Burkitt淋巴瘤中过表达。CLIN CANCER RES近期发表了一篇文章,研究6种不同B细胞淋巴瘤BCLW和其他抗凋亡BCL2家族成员的表达,以进一步研究BCLW对B细胞淋巴瘤的作用以及其对BCL2抑制剂耐药的影响。

Blood:brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。

首次接受治疗的60岁及以上的霍奇金淋巴瘤(HL)患者,由于治疗相关的毒性作用和并发症,可选择的治疗方式很少,而且预后较差。现研究人员进行一非盲、非随机的II期研究,评估brentuximab vedotin(BV)单一疗法、BV+达卡巴嗪(DTIC)和BV+苯达莫司汀用于霍奇金淋巴瘤老年患者的耐受性、疗效和反应持续时间。

Blood:基线代谢性肿瘤体积对早期霍奇金淋巴瘤的预测意义

为更好的筛查早期霍奇金淋巴瘤(HL)的高危患者,研究人员对基线PET/CT作为总体肿瘤负荷检测方法进行验证。研究人员筛选临床试验H10(NCT00433433)的标准臂里有基线PET和阿霉素、博来霉素、长春花碱和达卡巴嗪治疗两个疗程后的即时PET(iPET2)相关数据的I-II期的HL患者。基线PET对总体代谢肿瘤体积(TMTV)进行检查。IPET2的结果用Deauville量表标记阴性(DS1-